&NA;BAY X 3702 is the first selective and high-affinity serotonin1A receptor agonist to have potent neuroprotective activity in rodent models of permanent focal cerebral ischaemia and acute subdural haematoma with an extended therapeutic time window and a good toxicological profile. Consequently, BAY X 3702 may represent a new pharmacological approach for the the treatment of acute ischaemic stroke.BAY X 3702 is a novel aminomethylchroman derivative with high affinity for serotonin1A receptors. It is in phase II of development with Bayer in Germany for acute ischaemic stroke and traumatic brain injury.